On the treatment of bipolar affective disorder

Petrova N.N.

doi:https://doi.org/10.17116/jnevro202212201280

Close metadata

Recommended articles:

Aripiprazole in the treatment of psychiatric disorders in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):38-47

The gut microbiota in bipolar disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33

Metabolic syndrome and antipsychotic therapy of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170

Pathogenetic interrelations of hypogonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23

The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104

Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50

Search for risk factors for slowed intra-atrial conduction in patients with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):111-116

Abstract:

In the scientific review, in order to highlight the problem of bipolar affective disorder, a systematic review of the literature in PubMed and Google was conducted, epidemiological data were presented, issues of systematization and pharmacotherapy were considered, including modern meta-analyses and recommendations, including the effectiveness and safety of antipsychotic therapy. Special attention is paid to the place of quetiapine in the treatment of both manic and depressive symptoms of bipolar disorder. Relevant full-text articles, systematic reviews, meta-analyses identified by keywords were analyzed. The review did not include publication of clinical trial results.

Keywords:

bipolar disorder

antipsychotics

quetiapine

Kventiax

efficacy and safety

Authors:

Petrova N.N.

Saint-Petersburg State University

ORCID: 0000-0003-4096-6208

Received:

01.12.2022

Accepted:

03.12.2022

Close metadata

References:

Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Prim. 2018;4:18008. https://doi.org/10.1038/nrdp.2018.8
Carvalho A, Firth J, Vieta E. Bipolar Disorder. N Engl J Med. 2020;383(1):58-66. https://doi.org/10.1056/NEJMRA1906193
Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561-1572. https://doi.org/10.1016/S0140-6736(15)00241-X
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edn. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th Edn. Washington DC: American Psychiatric Association; 2013.
Goodwin GM, Geddes JR. What is the heartland of psychiatry? Br J Psychiatry. 2007;189-191.
Alonso J, Petukhova M, Vilagut G, Chatterji S, Heeringa S, Üstün TB, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol Psychiatry. 2011;16(12):1234-1246.
Kamali M, Reilly-Harrington NA, Chang WC, et al. Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. J Affect Disord. 2019;259:164-172. Epub 2019 Aug 19. https://doi.org/10.1016/j.jad.2019.08.032
Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543-552. https://doi.org/10.1001/archpsyc.64.5.543
Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalenceand correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241-251. https://doi.org/10.1001/archgenpsychiatry.2011.12
Cloutier M, Greene M, Guerin A, Touya M, Wu E. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45-51. https://doi.org/10.1016/j.jad.2017.09.011
Vieta E. The bipolar maze: a roadmap through translational psychopathology. Acta Psychiatr Scand. 2014;129:323-327.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C: American Psychiatric Association; 2013.
World Health Organization. Global Tuberculosis Report 2019. WHO; 2019.6. Doherty AM, Kelly J, McDonald C, O’Dywer AM, Keane J, Cooney J. A review of the interplay between tuberculosis and mental health. Gen Hosp Psychiatry. 2013;35(4):398-406. https://doi.org/10.1016/j.genhosppsych.2013.03.018
Vujnovic M, Manukhina O, Reed GM, Pavlos N. Theodorakis PN, Fountoulakis KN. ICD-11 revision of mental disorders: the global standard for health data, clinical documentation, and statistical aggregation. Consortium Psychiatricum. 2021;2(2):3-6. https://doi.org/10.17816/CP74
Samalin L, Murru A, Vieta E. Management of inter-episodic periods in patients with bipolar disorder. Expert Rev Neurother. April 2016. https://doi.org/10.1080/14737175.2016.1176530
National Institute for Health and Care Excellence: Bipolar disorder: assessment and management. Clinical guideline [CG185] [internet]. 2014. (2016 update) [cited 6 June 2017]. https://www.nice.org.uk/guidance/cg185.
Practice guideline for the treatment of patients with Bipolar disorder [internet]. American Psychiatric Association [cited 20 March 2018]. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf
Zhornitsky S, Potvin S, Moteshafi H, et al. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol. 2011;26:183-192.
Keramatian K, Chakrabarty T, Saraf G, Yatham LN. New Developments in the Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder: a Systematic Review of Recent Randomized Controlled Trials. Curr Psychiatry Rep. 2021;23(7):39. https://doi.org/10.1007/s11920-021-01252-w
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170.
McGirr A, Vöhringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry. 2016;3(12):1138-1146. https://doi.org/10.1016/S2215-0366(16)30264-4
Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-1262. https://doi.org/10.1176/appi.ajp.2013.13020185
Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010;13(1):5-14. https://doi.org/10.1017/S1461145709990344
Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47(2):43-52. https://doi.org/10.1055/s-0033-1363258
Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: a systematic review and network meta-analysis. World J Biol Psychiatry. 2018;19(8):586-601. https://doi.org/10.1080/15622975.2017.1285050
Kishi T, Yoshimura R, Sakuma K, et al. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network metaanalysis of phase 3 trials in Japan. Neuropsychopharmacology Reports. 2020;40:417-422. https://doi.org/10.1002/npr2.12137
Kadakia A, Dembek C, Heller V, et al. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC Psychiatry. 2021;21:249. https://doi.org/10.1186/s12888-021-03220-3
Ketter TA, Miller S, Dell’Osso B, Wang PW.Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. J Affect Disord. 2016;191:256-273. Epub 2015 Nov 25. https://doi.org/10.1016/j.jad.2015.11.002
Kim TT, Dufour S, Xu C, et al. Predictive modeling for response to lithium and quetiapine in bipolar disorder. Bipolar Disord. 2019;21(5):428-436. Epub 2019 Feb 27. https://doi.org/10.1111/bdi.12752
Kishi T, Ikuta T, Matsuda Y, et al. Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis. Neuropsychopharmacol Rep. 2019;39(3):256-259. Epub 2019 Jul 8. https://doi.org/10.1002/npr2.12070
Swartz HA, Rucci P, Thase ME, et al. Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression: A Randomized Controlled Trial. J Clin Psychiatry. 2018;79(2):16m11027. https://doi.org/10.4088/JCP.16m11027
Keck PE Jr. Monitoring pharmacotherapy response, safety, and tolerability to enhance adherence in bipolar disorder. J Clin Psychiatry. 2014;75:e12.
Torrent C, Amann B, Sanchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118:4-18.
Fang F, Wang Z, Wu R, et al. Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder? Expert Rev Neurother. 2017;17:407-418.
Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9:e94112.
Grootens KP, Meijer A, Hartong EG, et al. Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder. Eur J Clin Pharmacol. 2018;74:1485-1489.
Fang F, Sun H, Wang Z, et al. Antipsychotic drug-induced somnolence: incidence, mechanisms, and management. CNS Drugs. 2016;30:845-867.
Bai Y, Yang H, Chen G, et al. Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials. J Clin Psychopharmacol. 2020;40:167-179. https://doi.org/10.1097/jcp.0000000000001169
Yaramala SR, McElroy SL, Geske J, et al.The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. J Affect Disord. 2020;266:772-781. Epub 2018 Sep 12. https://doi.org/10.1016/j.jad.2018.09.025
Gao K, Su M, Ganocy SJ, et al. Longitudinally Measured Changes in Somnolence Severity With a Visual Analog Scale in a Randomized Lithium Versus Quetiapine-IR Study in Bipolar Disorder. J Clin Psychopharmacol. 2019;39(3):249-253. https://doi.org/10.1097/JCP.0000000000001031
Verdolini N, Hidalgo-Mazzei D, Del Matto L, et al. Long-term treatment of bipolar disorder type I: A systematic and critical review of clinical guidelines with derived practice algorithms. International Journal of Psychiatry and Neurosciences. 2021;23(4):324-340. https://doi.org/10.1111/bdi.13040
Soeiro-De-Souza MG, Dias VV, Missio G, et al. Role of quetiapine beyond its clinical efficacy in bipolar disorder: from neuroprotection to the treatment of psychiatric disorders. Experimental and Therapeutic Medicine. 2015;9:643-652.
Muneer A. Pharmacotherapy of Bipolar Disorder with Quetiapine: A Recent Literature Review and an Update. Clinical Psychopharmacology and Neuroscience. 2015;13(1):25-35.
Keramatian K, Chakrabarty T, Saraf G, Yatham LN. New Developments in the Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder: a Systematic Review of Recent Randomized Controlled Trials. Curr Psychiatry Rep. 2021;23(7):39.
Murasaki M, Koyama T, Kanba S, et al. Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression. Psychopharmacology (Berl). 2018;235(10):2859-2869. Epub 2018 Aug 1. https://doi.org/10.1007/s00213-018-4977-6
Kishi T, Ikuta T, Sakuma K, et al. Comparison of quetiapine immediate- and extended-release formulations for bipolar depression: A systematic review and network meta-analysis of double-blind, randomized placebo-controlled trials. J Psychiatr Res. 2019;115:121-128. Epub 2019 May 20. https://doi.org/10.1016/j.jpsychires.2019.05.020
Cutler AJ, Datto C, Nordenhem A, et al. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Clin Ther. 2011;33(11):1643-1658.
Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett. 2010;479:317-320. https://doi.org/10.1016/j.neulet.2010.05.088
Endicott J, Rajagopalan K, Minkwitz M, Macfadden W; BOLDER Study Group. A randomized, double blind, placebo controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol. 2007;22:29-37.
Endicott J, Paulsson B, Gustafsson U, Schiöler H, Hassan M. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep. J Affect Disord. 2008;111:306-319.
de Miranda AS, Moreira FA, Teixeira AL. The preclinical discovery and development of quetiapine for the treatment of mania and depression. Expert Opinion on Drug Discovery. 2017;12(5):525-535. https://doi.org/10.1080/17460441.2017.1304378
Post-authorisation safety and efficacy study of quetiapine (Kventiax) in the treatment of schizophrenia and bipolar mania. Data on file, Krka d.d., Novo mesto, Slovenia. 2010.
Bui K. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Curr Med Res Opin. 2013;29(7):813-825. https://cr.minzdrav.gov.ru › recomend
Clinical guidelines «Bipolar affective disorder» (approved by the Russian Ministry of Health), 2021. https://cr.minzdrav.gov.ru/schema/675_1
Modesto-Lowe V, Harabasz AK, Walker SA. Quetiapine for primary insomnia: Consider the risks. Cleveland Clinic Journal of Medicine. 2021;88(5):286-294. https://doi.org/10.3949/ccjm.88a.20031
Coe HV, Hong IS. Safety of Low Doses of Quetiapine When Used for Insomnia. Ann Pharmacother. 2012;46:718-722.